Drug Search Results

Condoliase

Alternative Names: condoliase, si-6603, si6603, si 6603
Latest Update: 2024-07-15
Latest Update Note: News Article

Product Description

Mechanisms of Action: Glycosaminoglycan Degrader

Novel Mechanism: Yes

Modality: Peptide/Protein

Route of Administration: Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Japan

Approved Indications: None

Known Adverse Events: None

Company: Seikagaku
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Condoliase

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Intervertebral Disc Displacement

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
Discovery 6603 Study	P3	Completed	Intervertebral Disc Displacement	2022-08-03	86%

Recent News Events

Date	Type	Title
07/15/2024	News Article	Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024
06/24/2024	News Article	Ferring to Present New Data Analyses at ASPN 2024 for SI-6603, an Investigational Treatment for Lumbar Disc Herniation
05/08/2024	PubMed	Immediate Effects, Detailed Clinical Outcomes, and Prognostic Factors of Chemonucleolysis Using Condoliase for Lumbar Disc Herniation.
05/08/2024	PubMed	Changes in Intervertebral Disc Properties after Intradiscal Injection of Condoliase for Painful Lumbar Disc Herniation.
04/08/2024	News Article	Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024
11/02/2023	PubMed	Psychological Factors Can Affect the Clinical Outcome of Chemonucleolysis with Condoliase in Patients with Lumbar Disk Herniation.
05/26/2023	News Article	Ferring Announces Positive Topline Phase 3 Results for SI-6603, an Investigational Treatment for Lumbar Disc Herniation

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions